CEL-SCI Targets Summer Start for Key Multikine Trial as Costs Decline
Event summary
- CEL-SCI plans to begin U.S. confirmatory trial for Multikine in head and neck cancer patients this summer, aiming for accelerated approval.
- Q1 2026 net loss narrowed to $5.5M from $7.1M year-over-year as R&D expenses dropped by $0.7M.
- Company submitted Breakthrough Medicine Designation application for Multikine in Saudi Arabia during H2 2025.
- Multikine Phase 3 study showed 73% 5-year survival rate vs. 45% with standard care alone.
The big picture
CEL-SCI is betting on its confirmatory trial to secure accelerated approval for Multikine, a therapy that has shown promising survival benefits in head and neck cancer. The company's cost reductions suggest improved financial discipline as it pursues regulatory milestones. Success in the U.S. and Saudi Arabia could position Multikine as a first-line treatment option in key markets.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept early tumor response data for accelerated approval of Multikine.
- Trial Execution
- The pace at which CEL-SCI and Ergomed can enroll 212 patients in the confirmatory study.
- Commercial Strategy
- How Saudi Arabia's potential Breakthrough Medicine Designation could impact Multikine's global market access.
Related topics